Alkaladi Ali, Abdelazim Aaser Mohamed, Afifi Mohamed
Department of Biological Sciences, Faculty of Science, King Abdulaziz University, North Campus, P.O. Box 11508, Jeddah 21463, Saudi Arabia.
Department of Biochemistry, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44511, Egypt.
Int J Mol Sci. 2014 Jan 28;15(2):2015-23. doi: 10.3390/ijms15022015.
The use of nanoparticles in medicine is an attractive proposition. In the present study, zinc oxide and silver nanoparticles were evaluated for their antidiabetic activity. Fifty male albino rats with weight 120 ± 20 and age 6 months were used. Animals were grouped as follows: control; did not receive any type of treatment, diabetic; received a single intraperitoneal dose of streptozotocin (100 mg/kg), diabetic + zinc oxide nanoparticles (ZnONPs), received single daily oral dose of 10 mg/kg ZnONPs in suspension, diabetic + silver nanoparticles (SNPs); received a single daily oral dose of SNP of 10 mg/kg in suspension and diabetic + insulin; received a single subcutaneous dose of 0.6 units/50 g body weight. Zinc oxide and silver nanoparticles induce a significant reduced blood glucose, higher serum insulin, higher glucokinase activity higher expression level of insulin, insulin receptor, GLUT-2 and glucokinase genes in diabetic rats treated with zinc oxide, silver nanoparticles and insulin. In conclusion, zinc oxide and sliver nanoparticles act as potent antidiabetic agents.
纳米颗粒在医学中的应用是一个颇具吸引力的提议。在本研究中，对氧化锌和银纳米颗粒的抗糖尿病活性进行了评估。使用了50只体重为120±20克、年龄为6个月的雄性白化大鼠。动物分组如下：对照组，未接受任何治疗；糖尿病组，接受单次腹腔注射链脲佐菌素（100毫克/千克）；糖尿病+氧化锌纳米颗粒组（ZnONPs），接受每日单次口服剂量为10毫克/千克的ZnONPs悬浮液；糖尿病+银纳米颗粒组（SNPs），接受每日单次口服剂量为10毫克/千克的SNP悬浮液；糖尿病+胰岛素组，接受单次皮下注射剂量为0.6单位/50克体重。氧化锌和银纳米颗粒可显著降低糖尿病大鼠的血糖，提高血清胰岛素水平、葡萄糖激酶活性以及胰岛素、胰岛素受体、葡萄糖转运蛋白2（GLUT-2）和葡萄糖激酶基因的表达水平。在用氧化锌、银纳米颗粒和胰岛素治疗的糖尿病大鼠中均是如此。总之，氧化锌和银纳米颗粒可作为有效的抗糖尿病药物。
